Scripps Research

San Diego, California
Ernest and Jean Hahn Professor at the Skaggs Institute for Chemical Biology

Research

Click here to read about Dr. Schimmel’s latest published work supported by NFCR

One of the most fundamental questions facing scientists today is how seemingly normal cells become cancerous. To better understand how this happens, Dr. Paul Schimmel has dedicated more than 40 years to examining the minute forms and intricate functions of molecular biology.

Dr. Schimmel, a world-renowned biophysical chemist and pioneer in translational medicine, developed the concept of expressed sequence tags in 1983, an approach employed for the Human Genome Project. During his career-long study of essential enzymes, he worked on an enzyme-directed genetic code, known as aminoacyl-tRNA synthetase (aaRS). Humans express 20 different aaRS enzymes, each playing a pivotal role in gene expression. With NFCR funding since 1994, Dr. Schimmel has advanced our understanding of the important role these essential enzymes play in defining the genetic code. Strong associations of some of these enzymes to human diseases has been revealed as well. These associations are now believed to be related to new functions of these proteins studied by Schimmel and collaborator, NFCR-supported scientist, Dr. Xiang-Lei Yang. It now appears that, with these proteins, treatable diseases include chronic and acute inflammation, neuropathy, and cancer progression and metastasis.

One aaRS, SerRS, possesses both anti-tumor and anti-metastasis properties. The scientists showed that SerRS inhibits a pro-cancer gene that triggers release of VEGF, a blood vessel formation factor. Without their own blood supply, tumors are deprived of oxygen and nutrients required for growth. In addition, they discovered that SerRS regulates many immune system-related molecules, implicating a role of SerRS in cancer metastasis.

This research is being conducted in triple negative breast cancer models and tissue samples from patients. They have discovered the expression of SerRS positively correlates with greater survival in breast cancer patients. The results also demonstrate SerRS is significantly downregulated during metastasis, suggest that SerRS is a suppressor of breast cancer and its metastasis. Similar findings of SerRS expression has been found in tissue samples of brain, esophageal, kidney (clear cell), rectal, stomach, and thyroid cancers.  Their significant research may lead to novel therapeutic applications for these cancers.

Dr. Schimmel’s team discovered that one type of tRNA – TyrRS – plays an important role in platelet production and maintenance. Platelets are the tiny blood vessels responsible for forming blood clots; they are often damaged during chemotherapy and cause dangerous bleeding disorders. Dr. Schimmel’s team is developing a TyrRS-based treatment that corrects this damaging side effect.

Bio

Paul Schimmel, Ph.D., is a biophysical chemist and he received his B.A. in biochemistry and biophysics from Ohio Wesleyan University in 1962, and then went on to earn his Ph.D. from Massachusetts Institute of Technology (MIT). Currently, Dr. Schimmel is the Ernest and Jean Hahn Professor of Molecular Biology and Chemistry at The Skaggs Institute for Chemical Biology at Scripps Research. He formerly was the John D. and Catherine T. MacArthur Professor of Biochemistry and Biophysics in the Department of Biology at MIT.  He is now MacArthur professor emeritus.

Throughout his career, Dr. Schimmel has received numerous honors and awards, including: the American Chemical Society’s Pfizer Award in Enzyme Chemistry, the Biophysical Society’s Emily M. Gray Award for Significant Contributions to Education in Biophysics, the Chinese Biopharmaceutical Association Brilliant Achievement Award, the Stein and Moore Award of the Protein Society, the American Chemical Society Kathryn C. Hach Award for Entrepreneurial Success, and the ARCS Foundation Scientist of the Year. He is an elected member of the American Academy of Arts and Sciences, the National Academy of Sciences, the American Philosophical Society, the National Academy of Medicine, and the National Academy of Inventors. He has also been active in many scientific and academic organizations and committees, including serving as Chairman of the Division of Biological Chemistry of the American Chemical Society. In addition to these honors and positions, Ohio Wesleyan University (his undergraduate alma mater) conferred on him an honorary Doctor of Science Degree.

Dr. Schimmel has given many honorary lectures, including the Peter Debye Lectures (Cornell University), the Sherman Beychok Lecture (Columbia University), the Reilly Lectures (University of Notre Dame), the Mildred Cohn Lecture (University of Pennsylvania School of Medicine), the University Lecture Series (University of Texas Health Sciences Center (Dallas), the Stanley Gill Memorial Lecture (University of Colorado), the Sir Hans Krebs Lecture (Sheffield, UK), the Nucleic Acids Award Lecture (Biochemical Society and Royal Society of Chemistry, UK), Henry Kamin Lecture (Duke University), the Perlman Lecture Award (American Chemical Society) and the Marker Lecture Series (Pennsylvania State University).

Dr. Schimmel is the author or co-author of more than 500 scientific papers and a widely used three-volume textbook on biophysical chemistry, and he served on the editorial board for numerous scientific journals.

Related Content

7 Facts You Need to Know About Blood Cancers

Genetic Testing: Learning More About Your Cancer Risk

Genetic testing can be an important tool in helping patients learn about their inherited cancer risk, but the results are not always as clear as patients might expect. Just as traits such as hair color and eye color can be passed down from parents to their children, so too can the risk for developing certain types of cancer. Scientists know that certain inherited gene mutations — small changes in a person’s DNA — can increase a person’s risk for developing diseases such as breast cancer, ovarian cancer, and colon cancer. Genetic testing examines a person’s DNA to determine if such mutations are present, helping patients better understand their cancer risk and, in some cases, allowing them to take charge of their health before receiving a devastating diagnosis. Understanding the Basics of Genetic Testing Only five to 10 percent of all cancers are believed to be tied to an inherited gene mutation.1 Genetic testing can help determine whether an individual has inherited a specific gene mutation (or mutations) that put him or her at higher risk for developing certain cancers. Most genetic tests require a small blood sample from the patient, but some tests can be performed using urine, saliva, or a cheek swab. The sample is sent to a special laboratory and results are usually provided to the patient’s doctor or genetic counselor within several weeks.2 Genetic testing can return one or a combination of the following results: Positive: The laboratory identified a genetic mutation that is associated with an inherited cancer risk.2 Negative: The laboratory did not find the specific genetic mutation (or mutations) that the test was designed to detect.2 Inconclusive: The laboratory was not able to determine whether a specific genetic mutation (or mutations) was present in the sample provided.2 Variance of Uncertain Significance: The laboratory identified a genetic mutation that has not been previously associated with cancer.2 No test can provide exact answers about a person’s inherited cancer risk. Genetic testing can tell you whether a specific genetic mutation is present in your DNA, but it cannot tell you for certain that you will develop the disease associated with that mutation later in life.3 Knowing Your Cancer Risk: Is Genetic Testing Right for You? Doctors often only recommend genetic testing for patients whose families have a history of certain cancers or patterns of cancer. According to the American Cancer Society, people who meet the following criteria might consider genetic testing: Cancer diagnoses in multiple first-degree relatives, including parents, siblings, or children1 Numerous relatives on one side of the family who have been diagnosed with the same cancer1 Family history of cancers linked to a single gene mutation, such as breast cancer, ovarian cancer, or pancreatic cancer1 Family member(s) who has been diagnosed with more than one type of cancer1 Family member(s) who has been diagnosed with cancer at a younger age than typically seen for that cancer, such as colon cancer1 Close relatives who have been diagnosed with cancers linked to rare hereditary cancer syndromes, such as Hereditary Breast & Ovarian Cancer Syndrome (HBOC), Cowden Syndrome, or Lynch Syndrome1 Family member(s) who has been diagnosed with […]

Multiple Myeloma: A Rare But Very Real Cancer

On May 23, 2018, my mother, Susan Williams, was admitted to UNC Rex Hospital in our home town of Raleigh, North Carolina, after being told that some “abnormalities” had shown up in her blood test. Several months earlier, my mom experienced excruciating pain around her rib cage and back that caused her to eventually become immobile. She met with multiple specialists to get opinions on what might be wrong. She was told it was probably a pulled muscle, maybe potential nerve damage, even osteoporosis. That is when we finally found out she had several fractures in her ribs, pelvis, and multiple crushed vertebrae. This explained the pain she endured. However, It wasn’t until that day in May when we finally got the answer we had been waiting for. The dreadful diagnosis that would change our family and, more greatly, my mom’s life forever. Multiple Myeloma is a cancer of the plasma cells which are white blood cells that help fight infection and are made in the bone marrow. The more of these cells that have myeloma, the more severe the symptoms are for patients; such as weak bones and a higher risk of infection— which often is what will lead to their demise. There is currently no cure for Multiple Myeloma. There are standard treatment options available to help manage the progression. A common treatment is a Stem Cell Transplant or Bone Marrow Transplant, where patients are dosed with intense chemotherapy that will hopefully kill the myeloma cells and replace enough of them with healthy cells. The majority of Myeloma patients will only need to have this transplant once. My mother was an exception. She had to go through it twice. After transplant, patients will often try different maintenance chemotherapies until one keeps their myeloma cell counts low and manageable. Multiple Myeloma never reaches remission because the disease is always in the blood and most likely will come back. Again, there is no cure. Learn more about Multiple Myeloma on NFCR’s blog here. Spreading awareness about this disease is crucial because it is difficult to diagnose correctly let alone detect early. It is also hard to track how well patients will respond to treatments and if treatment will even work at all, which is a discouraging fate my mom has been faced with. There are still a lot of unknowns about this cancer and we need to support research to be able to answer those questions. Every day we constantly prepare for the worst. Our hope is that my mom will be able to see the day when advancements in cancer research will save her life. March is Multiple Myeloma Awareness Month and I truly believe that awareness may help bring a cure someday.  It’s heartbreaking seeing someone you love suffer every day. We are faced with overwhelming feelings of helplessness when we can’t take their pain away. I wanted to do something more to help my mom which is what motivated me to volunteer my time to help the National Foundation for Cancer Research (NFCR) and their mission – Research for a Cure. Everyone has something to give to […]